
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12064/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Diagnostic Delays on Lung Cancer Survival Outcomes: A Population Study of the US SEER-Medicare Database. JCO Oncology Practice, 2022, 18, e877-e885.	2.9	4
2	Performance status (<scp>PS</scp>) as a predictor of poor response to immune checkpoint inhibitors (<scp>ICI</scp>) in recurrent/metastatic head and neck cancer (<scp>RMHNSCC</scp>) patients. Cancer Medicine, 2022, 11, 4104-4111.	2.8	11
3	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. Cancer Treatment and Research Communications, 2021, 28, 100416.	1.7	0
4	Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 523-530.	2.6	4
5	Effect of Clinical Trial Participation on Costs to Payers in Metastatic Non–Small-Cell Lung Cancer. JCO Oncology Practice, 2021, 17, e1225-e1234.	2.9	3
6	A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients. Respiratory Medicine Case Reports, 2021, 34, 101541.	0.4	5
7	Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer. Cureus, 2021, 13, e18804.	0.5	0
8	High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors. Journal of Palliative Medicine, 2021, , .	1.1	0
9	Timing of postoperative radiation therapy and survival in resected salivary gland cancers: Long-term results from a single institution. Oral Oncology, 2021, 123, 105626.	1.5	1
10	A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clinical Cancer Research, 2020, 26, 837-845.	7.0	120
11	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. , 2020, 8, e001009.		30
12	<i>MYCN</i> drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. Genes and Development, 2020, 34, 1210-1226.	5.9	46
13	Aldosterone-Secreting Adrenocortical Carcinoma Presenting With Cardiac Arrest. Journal of the Endocrine Society, 2019, 3, 1678-1681.	0.2	2
14	Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Science Signaling, 2019, 12, .	3.6	130
15	Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome. BMC Cancer, 2019, 19, 70.	2.6	6
16	Sarcoidosis Presenting as Isolated Anasarca and Hypercalcemia. American Journal of Medicine, 2019, 132, e13-e14.	1.5	0
17	Racial disparity in oncologic and qualityâ€ofâ€life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. Cancer, 2018, 124, 2841-2849.	4.1	7
18	Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. Journal of Thoracic Oncology, 2018, 13, 649-659.	1.1	35

2

#	Article	IF	CITATIONS
19	A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Investigational New Drugs, 2018, 36, 836-847.	2.6	63
20	Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. Head and Neck, 2018, 40, 584-589.	2.0	13
21	Pregnancy Screening in Patients With Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 99-103.	4.9	4
22	Characterizing Potentially Preventable Cancer- and Chronic Disease–Related Emergency Department Use in the Year After Treatment Initiation: A Regional Study. Journal of Oncology Practice, 2018, 14, e176-e185.	2.5	74
23	An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, Bl 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer, 2017, 104, 126-130.	2.0	33
24	Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN. Clinical Cancer Research, 2017, 23, 2442-2450.	7.0	102
25	Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. Laryngoscope, 2017, 127, 1583-1588.	2.0	8
26	Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 145-151.	1.1	48
27	Phase 2 Study of Erlotinib in Combination WithÂLinsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 2017, 18, 34-42.e2.	2.6	29
28	Concurrent cetuximab and postoperative radiation in resected highâ€risk squamous cell carcinomas of the head and neck: A singleâ€institution experience. Head and Neck, 2016, 38, 1318-1323.	2.0	12
29	Value-Based Care in Lung Cancer. Oncologist, 2016, 21, 903-906.	3.7	12
30	Spontaneous Regression of Non–Small-Cell Lung Cancer in AIDS After Immune Reconstitution. Journal of Thoracic Oncology, 2015, 10, e1-e2.	1.1	10
31	Detection of HPV in oral rinse samples from OPSCC and non-OPSCC patients. BMC Oral Health, 2015, 15, 126.	2.3	17
32	The Pseudocavitation Sign of Lung Adenocarcinoma. Journal of Thoracic Imaging, 2015, 30, 308-313.	1.5	17
33	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With <i>IKZF3</i> Deletion and <i>TP53</i> Mutation. American Journal of Clinical Pathology, 2015, 144, 263-270.	0.7	10
34	Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes Care, 2015, 38, e137-e138.	8.6	138
35	Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. Oncologist, 2014, 19, 175-176.	3.7	21
36	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. Journal of Molecular Diagnostics, 2014, 16, 56-67.	2.8	234

#	Article	IF	CITATIONS
37	Occult Primary, Version 3.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 969-974.	4.9	27
38	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. Journal of Clinical Oncology, 2013, 31, 1415-1421.	1.6	180
39	EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers. Journal of Thoracic Oncology, 2013, 8, e6-e7.	1.1	11
40	Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels. PLoS ONE, 2013, 8, e64795.	2.5	258
41	Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy. Cancers, 2012, 4, 969-988.	3.7	45
42	Is There a Role for Whole Brain Radiotherapy in the Treatment of Leptomeningeal Metastases?. Journal of Thoracic Oncology, 2012, 7, 1204.	1.1	7
43	A 66-Year-Old Woman With Newly Diagnosed Oligometastatic Non–Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 297-301.	4.9	1
44	A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer, 2012, 12, 449.	2.6	26
45	Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.	27.0	6,820
46	Occult Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 1358-1395.	4.9	41
47	Radiation-Induced Myelopathy. Archives of Neurology, 2011, 68, 1608.	4.5	25
48	Evaluation of Failure Patterns Using Trimodality in Non-Small Cell Lung Cancer. World Journal of Oncology, 2011, 2, 64-69.	1.5	1
49	Maintenance Chemotherapy in Non–Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 815-821.	4.9	27
50	Intradural intramedullary spinal cord metastasis due to mesothelioma. Journal of Neuro-Oncology, 2010, 97, 133-136.	2.9	24
51	Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 3076-3083.	1.6	402
52	Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation. Clinical Cancer Research, 2010, 16, 5260-5268.	7.0	389
53	Cancer pain: Perspectives of a medical oncologist. Current Pain and Headache Reports, 2008, 12, 270-276.	2.9	3
54	Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes. Annals of Thoracic Surgery, 2008, 86, 1632-1639.	1.3	96

#	Article	IF	CITATIONS
55	Occult Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 1026.	4.9	2
56	Treatment of Recurrent Squamous Cell Carcinoma of the Skin With Cetuximab. Archives of Dermatology, 2007, 143, 889-92.	1.4	92
57	Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations. Clinical Cancer Research, 2007, 13, 4632s-4636s.	7.0	23